OTCMKTS:INVVY

Indivior - INVVY Stock Forecast, Price & News

$20.14

-0.91 (-4.32%)

(As of 11/30/2022 12:00 AM ET)

Add

Compare

Today's Range: $20.14
▼
$20.14
50-Day Range: $14.85
▼
$23.31
52-Week Range: $14.22
▼
$23.31

Volume: 315 shs
Average Volume: 3,429 shs
Market Capitalization: $2.76 billion

P/E Ratio: 19.18
Dividend Yield: N/A
Price Target: N/A

About Indivior (OTCMKTS:INVVY) Stock

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders. The company's product pipeline focuses on treating opioid use disorder, addiction, and schizophrenia. It markets and promotes SUBLOCADE injection for subcutaneous use; and SUBOXONE sublingual film, SUBOXONE sublingual tablet, and SUBUTEX sublingual tablet, as well as sells legacy products that include Temgesic, Burpex, and Buprenex. The company operates in approximately 40 countries worldwide. Indivior PLC has research collaboration agreement with Addex Therapeutics Ltd. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.

Receive INVVY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Indivior and its competitors with MarketBeat's FREE daily newsletter.

INVVY Stock News Headlines

November 14, 2022 | finance.yahoo.com

Indivior To Pay Over 100% Premium To Buy Opioid Focused Player Opiant Pharmaceuticals

October 12, 2022 | uk.investing.com

London midday: FTSE flat, sterling up as BoE confirms end of bond-buying programme By Sharecast - Investing.com UK

October 4, 2022 | uk.finance.yahoo.com

Aelis Farma CEO Pier Vincenzo Piazza Receives the EY Entrepreneur of the Year Award - Yahoo Finance UK

October 4, 2022 | businesswire.com

Aelis Farma CEO Pier Vincenzo Piazza Receives the EY Entrepreneur of the Year Award - Business Wire

September 30, 2022 | benzinga.com

Indivior Shareholders Approve Resolutions to Proceed with Additional U.S. Listing - Indivior (OTC:INVVY) - Benzinga

September 27, 2022 | finance.yahoo.com

Aelis Farma: Availability of the 2022 Half-year Financial Report - Yahoo Finance

September 26, 2022 | streetinsider.com

Aelis Farma reports 2022 half-year financial results and confirms its development objectives - StreetInsider.com

September 22, 2022 | streetinsider.com

Aelis Farma Will Participate in the Addiction 2022 Conference Dedicated to Innovation in the Treatment of Addictions - StreetInsider.com

September 7, 2022 | finance.yahoo.com

Indivior To Participate in Upcoming Investor Healthcare Events - Yahoo Finance

August 22, 2022 | streetinsider.com

Adial Pharmaceuticals (ADIL) Appoints Cary Claiborne as CEO - StreetInsider.com

August 18, 2022 | streetinsider.com

Addex Reports 2022 Half Year and Second Quarter Financial Results and Provides Corporate Update - StreetInsider.com

August 17, 2022 | benzinga.com

Hypocrisy All Around: Pfizer, NFL Are Hidden Sponsors Of Anti-Drug Group Fighting Against Cannabis Legali - Benzinga

August 15, 2022 | finance.yahoo.com

Addex and Indivior Extend GABAB Positive Allosteric Modulator Research Collaboration for Substance Use Disorders - Yahoo Finance

August 4, 2022 | nasdaq.com

Here's Why Momentum in Indivior PLC (INVVY) Should Keep going - Nasdaq

August 4, 2022 | finance.yahoo.com

Here's Why Momentum in Indivior PLC (INVVY) Should Keep going

July 28, 2022 | fool.co.uk

Are these 3 cheap stocks to buy after the latest results? - Motley Fool UK

July 28, 2022 | lse.co.uk

Indivior profits fall on higher costs ahead of US listing | Financial News - London South East

July 28, 2022 | marketwatch.com

Indivior 1H Pretax Profit Fell as Costs Rose - MarketWatch

July 20, 2022 | globenewswire.com

Global Naloxone Market to surpass US$ 2,460.2 Million by - GlobeNewswire

June 24, 2022 | marketwatch.com

Indivior Settles Opioid Addiction Treatment Litigation With Dr. Reddy's - MarketWatch

June 19, 2022 | streetinsider.com

Addex Terminates Dipraglurant Phase 2b/3 Study in Patients with Dyskinesia Associated with Parkinson's Disease due to Slow Recruitment Rate - StreetInsider.com

June 2, 2022 | uk.finance.yahoo.com

Two factors to watch at Indivior - Yahoo Finance UK

June 1, 2022 | morningstar.co.uk

TRADING UPDATES: Indivior, Diurnal start trials; Alien Metals tests - Morningstar

May 19, 2022 | finance.yahoo.com

For Mental Health Awareness Month, Indivior Offers Hope for Opioid Use Disorder Recovery Through One Man's Inspiring Story - Yahoo Finance

May 10, 2022 | finance.yahoo.com

Addex Shareholders Approve All Resolutions at Annual General Meeting - Yahoo Finance

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive INVVY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Indivior and its competitors with MarketBeat's FREE daily newsletter.

INVVY Company Calendar

Today: 11/30/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: OTCMKTS:INVVY
Previous Symbol: NASDAQ:INVVY
CUSIP: N/A
CIK: N/A
Web: www.indivior.com
Phone: 804-379-1090
Fax: 804-379-1215
Employees: 800
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): $1.05
Trailing P/E Ratio: 19.18
Forward P/E Ratio: 17.36
P/E Growth: N/A
Net Income: $205 million
Net Margins: 18.04%
Pretax Margin: 21.15%
Return on Equity: 66.83%
Return on Assets: 7.91%

Debt

Debt-to-Equity Ratio: 1.03
Current Ratio: 1.70
Quick Ratio: 1.58

Sales & Book Value

Annual Sales: $791 million
Price / Sales: 3.48
Cash Flow: $1.02 per share
Price / Cash Flow: 19.74
Book Value: $1.45 per share
Price / Book: 13.89

Miscellaneous

Outstanding Shares: 136,845,000
Free Float: N/A
Market Cap: $2.76 billion
Optionable: Not Optionable
Beta: 0.31

Key Executives

Mr. Mark Crossley
CEO & Exec. Director

Mr. Ryan Preblick
CFO & Exec. Director

Dr. Christian Heidbreder
Chief Scientific Officer

Mr. Jason Thompson
VP of Investor Relations

Ms. Cynthia Cetani
Chief Integrity & Compliance Officer

Mr. Jeffrey W. Burris (Age 50)
Chief Legal Officer

Mr. Jon Fogle
Chief HR Officer

Mr. Richard Simkin
Chief Commercial & Strategy Officer

Mr. Hillel West
Chief Manufacturing & Supply Officer

Ms. Nina DeLorenzo
Chief Global Impact Officer

Key Competitors

View All Competitors

INVVY Stock - Frequently Asked Questions

Should I buy or sell Indivior stock right now?: 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Indivior in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" INVVY shares.
View INVVY analyst ratings or view top-rated stocks.
How have INVVY shares performed in 2022?: Indivior's stock was trading at $17.19 on January 1st, 2022. Since then, INVVY stock has increased by 17.2% and is now trading at $20.14.
View the best growth stocks for 2022 here.
Are investors shorting Indivior?: Indivior saw a drop in short interest during the month of October. As of October 31st, there was short interest totaling 14,700 shares, a drop of 22.6% from the October 15th total of 19,000 shares. Based on an average daily trading volume, of 2,400 shares, the short-interest ratio is presently 6.1 days.
View Indivior's Short Interest.
What guidance has Indivior issued on next quarter's earnings?: Indivior updated its FY 2022 earnings guidance on Thursday, November, 3rd. The company provided EPS guidance of for the period. The company issued revenue guidance of $890.00 million-$915.00 million.

What is Indivior's stock symbol?: Indivior trades on the OTCMKTS under the ticker symbol "INVVY."
How do I buy shares of Indivior?: Shares of INVVY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Indivior's stock price today?: One share of INVVY stock can currently be purchased for approximately $20.14.
How much money does Indivior make?: Indivior (OTCMKTS:INVVY) has a market capitalization of $2.76 billion and generates $791 million in revenue each year. The company earns $205 million in net income (profit) each year or $1.05 on an earnings per share basis.
How many employees does Indivior have?: The company employs 800 workers across the globe.
How can I contact Indivior?: Indivior's mailing address is 10710 Midlothian Turnpike, North Chesterfield VA, 23235. The official website for the company is www.indivior.com. The company can be reached via phone at 804-379-1090, via email at investorrelations@indivior.com, or via fax at 804-379-1215.

This page (OTCMKTS:INVVY) was last updated on 11/30/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial